

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 December 2023 (28.12.2023)



(10) International Publication Number
WO 2023/249974 A2

- (51) **International Patent Classification:**
A61K 31/53 (2006.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/US2023/025791
- (22) **International Filing Date:**
20 June 2023 (20.06.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|------------|-------------------------------|----|
| 63/353,729 | 20 June 2022 (20.06.2022) | US |
| 63/444,523 | 09 February 2023 (09.02.2023) | US |
| 63/460,201 | 18 April 2023 (18.04.2023) | US |
| 63/470,621 | 02 June 2023 (02.06.2023) | US |
- (71) **Applicant:** INCYCLIX BIO, INC. [US/US]; 600 Park Office Drive, Suite 355, Research Triangle Park, NC 27709 (US).
- (72) **Inventors:** STRUM, Jay Copeland; c/o Incyclix Bio, Inc., 600 Park Offices Drive, Suite 355, Research Triangle Park, NC 27709 (US). BISI, John E.; c/o Incyclix Bio, Inc., 600


Park Offices Drive, Suite 355, Research Triangle Park, NC 27709 (US). **TRUB, Alec Gibson**; c/o Incyclix Bio, Inc., 600 Park Offices Drive, Suite 355, Research Triangle Park, NC 27709 (US).

(74) **Agent:** BELLOWS, Brent R. et al.; Knowles Intellectual Property Strategies, LLC, 400 Perimeter Center Terrace, Suite 200, Atlanta, GA 30346 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

(54) **Title:** CYCLIN-DEPENDENT KINASE 2 INHIBITORS FOR MEDICAL TREATMENT



(57) **Abstract:** Use of a pyrimidine-based selective cyclin-dependent kinase 2 (CDK2) of structure: (Compound I), or a pharmaceutically acceptable salt thereof or morphic form described herein for the treatment of disorders characterized by aberrant cellular division having amplified cyclin E activation and/or expression or aberrant cellular division disorders, CDK4/6 resistance, and/or endocrine therapy resistance, including but not limited to the treatment of tumors and cancers.

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*